| pubmed-article:21109548 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21109548 | lifeskim:mentions | umls-concept:C0014834 | lld:lifeskim |
| pubmed-article:21109548 | lifeskim:mentions | umls-concept:C0254610 | lld:lifeskim |
| pubmed-article:21109548 | lifeskim:mentions | umls-concept:C0015219 | lld:lifeskim |
| pubmed-article:21109548 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:21109548 | lifeskim:mentions | umls-concept:C0037628 | lld:lifeskim |
| pubmed-article:21109548 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:21109548 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:21109548 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:21109548 | pubmed:dateCreated | 2011-2-15 | lld:pubmed |
| pubmed-article:21109548 | pubmed:abstractText | Directed evolution was used to generate IL-15 mutants with increased solubility and cytoplasmic over-expression in Escherichia coli. A protein solubility selection method was used in which the IL-15 gene was expressed as an N-terminal fusion to chloramphenicol acetyltransferase (CAT) as reporter protein. Clones that grew in the presence of high concentrations of chloramphenicol were then screened by ELISA to assay the binding activity of the IL-15-CAT fusion to the IL-15R? Sushi domain. Two variants of IL-15, M38 and M253, containing five mutations and one mutation respectively, were selected with a dramatic improvement in solubility; the soluble concentration in cell culture was 12- to 18-fold higher, respectively, than for WT IL-15. Characterization of their binding to IL-15R? and their ability to stimulate the T-cell growth response showed that M38 binds as strongly as native IL-15 to IL-15R? and acts as an effective agonist of IL-15. | lld:pubmed |
| pubmed-article:21109548 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21109548 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21109548 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21109548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21109548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21109548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21109548 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21109548 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:21109548 | pubmed:issn | 1741-0134 | lld:pubmed |
| pubmed-article:21109548 | pubmed:author | pubmed-author:JacquesYannic... | lld:pubmed |
| pubmed-article:21109548 | pubmed:author | pubmed-author:DefontaineAla... | lld:pubmed |
| pubmed-article:21109548 | pubmed:author | pubmed-author:TellierCharle... | lld:pubmed |
| pubmed-article:21109548 | pubmed:author | pubmed-author:QuéménerAgnès... | lld:pubmed |
| pubmed-article:21109548 | pubmed:author | pubmed-author:SoléVéronique... | lld:pubmed |
| pubmed-article:21109548 | pubmed:author | pubmed-author:BéharGhislain... | lld:pubmed |
| pubmed-article:21109548 | pubmed:author | pubmed-author:MaillassonMik... | lld:pubmed |
| pubmed-article:21109548 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21109548 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:21109548 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21109548 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21109548 | pubmed:pagination | 283-90 | lld:pubmed |
| pubmed-article:21109548 | pubmed:meshHeading | pubmed-meshheading:21109548... | lld:pubmed |
| pubmed-article:21109548 | pubmed:meshHeading | pubmed-meshheading:21109548... | lld:pubmed |
| pubmed-article:21109548 | pubmed:meshHeading | pubmed-meshheading:21109548... | lld:pubmed |
| pubmed-article:21109548 | pubmed:meshHeading | pubmed-meshheading:21109548... | lld:pubmed |
| pubmed-article:21109548 | pubmed:meshHeading | pubmed-meshheading:21109548... | lld:pubmed |
| pubmed-article:21109548 | pubmed:meshHeading | pubmed-meshheading:21109548... | lld:pubmed |
| pubmed-article:21109548 | pubmed:meshHeading | pubmed-meshheading:21109548... | lld:pubmed |
| pubmed-article:21109548 | pubmed:meshHeading | pubmed-meshheading:21109548... | lld:pubmed |
| pubmed-article:21109548 | pubmed:meshHeading | pubmed-meshheading:21109548... | lld:pubmed |
| pubmed-article:21109548 | pubmed:meshHeading | pubmed-meshheading:21109548... | lld:pubmed |
| pubmed-article:21109548 | pubmed:meshHeading | pubmed-meshheading:21109548... | lld:pubmed |
| pubmed-article:21109548 | pubmed:meshHeading | pubmed-meshheading:21109548... | lld:pubmed |
| pubmed-article:21109548 | pubmed:meshHeading | pubmed-meshheading:21109548... | lld:pubmed |
| pubmed-article:21109548 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21109548 | pubmed:articleTitle | Evolution of interleukin-15 for higher E. coli expression and solubility. | lld:pubmed |
| pubmed-article:21109548 | pubmed:affiliation | Faculté des Sciences et des Techniques, Université de Nantes, UMR CNRS 6204, Biotechnologie, Biocatalyse, Biorégulation, 2 Rue de la Houssinière, BP 92208, Nantes F-44322, France. | lld:pubmed |
| pubmed-article:21109548 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21109548 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
